
đŠē CORRECTED PRESCRIPTION ANALYSIS & FINAL CLINICAL ASSESSMENT
Based on MedEx Bangladesh, Harrisonâs Internal Medicine, AHA/ASA & NICE Guidelines
āĻāĻĒāύāĻžāϰ āϏāĻāĻļā§āϧāύ āĻ āύā§āϝāĻžā§ā§ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ ā§Š āύāĻŽā§āĻŦāϰ āĻāώā§āϧāĻāĻŋ Cap. Algaba 50 mg (Pregabalin)āĨ¤ āĻāĻā§āϰ āĻŦāĻŋāĻļā§āϞā§āώāĻŖā§ āĻāώā§āϧāĻāĻŋāϰ āĻĒāϰāĻŋāĻā§ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āϝāĻžā§āύāĻŋāĨ¤ āĻāĻŦāĻžāϰ MedEx āĻĨā§āĻā§ āĻāϰ Generic, Therapeutic Class, Pharmacological Class, āĻĒā§āϰāϏā§āϤā§āϤāĻāĻžāϰāĻ āĻ āĻŽā§āϞā§āϝ āϝāĻžāĻāĻžāĻ āĻāϰā§āĻāĻŋāĨ¤
āĻĒā§āϰ⧠āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ āĻĒā§āύāϰāĻžā§ āĻĒāϰā§āϝāĻžāϞā§āĻāύāĻž āĻāϰ⧠āύāĻŋāĻā§ āϏāĻāĻļā§āϧāĻŋāϤ āĻŦāĻŋāĻļā§āϞā§āώāĻŖ āĻĻā§āĻā§āĻž āĻšāϞā§āĨ¤
đ¸ āϏāĻāĻļā§āϧāĻŋāϤ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ â C/C, O/E, ā§ŦāĻāĻŋ āĻāώā§āϧ āĻ Advice āĻāĻŋāĻšā§āύāĻŋāϤ āĻāĻŦāĻŋ
Clinical limitation: āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ āĻĨā§āĻā§ āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āϰā§āĻā§āϰ āĻāϤāĻŋāĻšāĻžāϏ āĻĒāĻžāĻā§āĻž āϝāĻžāĻā§āĻā§, āĻāĻŋāύā§āϤ⧠Stroke-āĻāϰ āĻĒā§āϰā§āύ⧠CT/MRI, āĻŦāϰā§āϤāĻŽāĻžāύ Neurological Examination āĻāĻŦāĻ āϰā§āĻā§āϰ āĻĒā§āϰā§āĻŖ āĻāĻĒāϏāϰā§āĻ āĻĒāĻžāĻā§āĻž āϝāĻžā§āύāĻŋāĨ¤ āϤāĻžāĻ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϤāĻŋāĻšāĻžāϏ, āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϰā§āĻ āĻāĻŦāĻ āĻāĻŋāĻāĻŋā§āϏāĻžāĻāϤ āĻ āύā§āĻŽāĻžāύ āĻāϞāĻžāĻĻāĻžāĻāĻžāĻŦā§ āĻāϞā§āϞā§āĻ āĻāϰāĻāĻŋāĨ¤
ā§§. Patient Information
| Information | Findings |
|---|---|
| Patient’s age | āϏāĻŽā§āĻāĻŦāϤ ā§Ģā§Ž āĻŦāĻāϰ |
| Date | ā§§ā§§ āĻ āĻā§āĻā§āĻŦāϰ ⧍ā§Ļ⧍ā§Ŧ āĻŦāϞ⧠āĻŽāύ⧠āĻšāĻā§āĻā§ |
| Treating specialty | Neuromedicine & Medicine |
| Documented disease | HTN, Ischemic Stroke |
| Number of prescribed drugs | ā§ŦāĻāĻŋ |
| Rehabilitation advice | Physiotherapy |
| Previous Stroke Imaging | āϏāĻāϝā§āĻā§āϤ āύā§āĻ |
Patient History â āĻāĻŋāĻāĻŋā§āϏāĻ āĻā§ āϞāĻŋāĻā§āĻā§āύ?
1. HTN â Hypertension
āĻŦāĻžāĻāϞāĻž: āĻāĻā§āĻ āϰāĻā§āϤāĻāĻžāĻĒāĨ¤
āĻāĻā§āĻ āϰāĻā§āϤāĻāĻžāĻĒ āĻŽāϏā§āϤāĻŋāώā§āĻā§āϰ āĻā§āĻ āĻ āĻŦā§ āϰāĻā§āϤāύāĻžāϞāĻŋāϰ āĻā§āώāϤāĻŋ āĻāĻāĻžāϤ⧠āĻĒāĻžāϰ⧠āĻāĻŦāĻ Ischemic āĻ Hemorrhagic Stroke-āĻāϰ āĻāĻāĻāĻŋ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āĻā§āĻāĻāĻŋāϰ āĻāĻžāϰāĻŖāĨ¤
Prescription-reading Confidence: 0.99
2. Ischemic Stroke
āĻŦāĻžāĻāϞāĻž: āĻŽāϏā§āϤāĻŋāώā§āĻā§ āϰāĻā§āϤ āϏāϰāĻŦāϰāĻžāĻš āĻŦāĻžāϧāĻžāĻā§āϰāϏā§āϤ āĻšāĻā§āĻžāϰ āĻāĻžāϰāĻŖā§ āϏāĻāĻāĻāĻŋāϤ āϏā§āĻā§āϰā§āĻāĨ¤
āĻāĻāĻāĻŋ āϰāĻā§āϤāύāĻžāϞāĻŋāϤ⧠Thrombus āĻ āĻĨāĻŦāĻž Embolus āĻĻā§āĻŦāĻžāϰāĻž āϰāĻā§āϤāĻĒā§āϰāĻŦāĻžāĻš āĻŦāĻžāϧāĻžāĻā§āϰāϏā§āϤ āĻšāϞ⧠āϏāĻāĻļā§āϞāĻŋāώā§āĻ āĻŽāϏā§āϤāĻŋāώā§āĻā§āϰ āĻ āĻāĻļā§ Ischemia āĻĻā§āĻāĻž āĻĻā§ā§āĨ¤
Prescription-reading Confidence: 0.98
3. Additional History
Ischemic Stroke-āĻāϰ āĻĒāϰ⧠āĻāϰāĻ āĻāĻāĻāĻŋ āϏāĻāĻā§āώāĻŋāĻĒā§āϤ āύā§āĻ āϰā§ā§āĻā§āĨ¤ āϏā§āĻāĻŋ āύāĻŋāϰā§āĻāϰāϝā§āĻā§āϝāĻāĻžāĻŦā§ āĻĒā§āĻž āϝāĻžāĻā§āĻā§ āύāĻžāĨ¤
āϤāĻžāĻ āϏā§āĻā§āϰā§āĻā§āϰ āϏāĻŽā§, āĻŽāϏā§āϤāĻŋāώā§āĻā§āϰ āĻāĻā§āϰāĻžāύā§āϤ āĻ āĻāĻļ āĻ āĻĨāĻŦāĻž āĻļāϰā§āϰā§āϰ āĻā§āύ āĻĒāĻžāĻļ āĻĻā§āϰā§āĻŦāϞâāĻāϏāĻŦ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰ⧠āĻŦāϞāĻž āϝāĻžāĻā§āĻā§ āύāĻžāĨ¤
⧍. C/C â Chief Complaints
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠C/C-āĻāϰ āύāĻŋāĻā§ āĻĒāĻžāĻā§āĻž āϝāĻžā§:
- HTN
- Ischemic Stroke
- āĻāĻāĻāĻŋ āĻ āϏā§āĻĒāώā§āĻ āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āύā§āĻāĨ¤
Clinical observation: āĻāĻāĻžāύ⧠āĻŽā§āϞāϤ āϰā§āĻā§āϰ āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āĻ āϏā§āϏā§āĻĨāϤāĻžāϰ āϤāĻĨā§āϝ āϞā§āĻāĻž āĻšā§ā§āĻā§āĨ¤ āĻŦāϰā§āϤāĻŽāĻžāύ āĻāĻĒāϏāϰā§āĻāĻā§āϞ⧠āĻĒā§āĻĨāĻāĻāĻžāĻŦā§ āĻŦāĻŋāϏā§āϤāĻžāϰāĻŋāϤ āĻāϞā§āϞā§āĻ āĻāϰāĻž āĻšā§āύāĻŋāĨ¤
āϝā§āĻŽāύ āĻšāĻžāϤ-āĻĒāĻž āĻĻā§āϰā§āĻŦāϞāϤāĻž, āĻŦā§āϝāĻĨāĻž, āĻāĻŋāύāĻāĻŋāύ āĻāϰāĻž, āĻšāĻžāĻāĻāĻžāϰ āĻ āϏā§āĻŦāĻŋāϧāĻž āĻ āĻĨāĻŦāĻž āĻŽāĻžāĻāϏāĻĒā§āĻļāĻŋāϤ⧠āĻāĻžāύâāĻāϏāĻŦā§āϰ āĻāĻĒāϏā§āĻĨāĻŋāϤāĻŋ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ āĻĨā§āĻā§ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āϝāĻžāĻā§āĻā§ āύāĻžāĨ¤
ā§Š. O/E â On Examination
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āϰāĻā§āϤāĻāĻžāĻĒā§āϰ āĻāĻāĻāĻŋ Reading āϰā§ā§āĻā§āĨ¤
BP: āϏāĻŽā§āĻāĻŦāϤ 110/80 mmHgāĨ¤
āϤāĻŦā§ āĻšāĻžāϤā§āϰ āϞā§āĻāĻž āĻ āϏā§āĻĒāώā§āĻāĨ¤ āĻŽā§āϞ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āϏāĻā§āĻā§ āĻŽāĻŋāϞāĻŋā§ā§ āύā§āĻā§āĻž āĻĒā§āϰā§ā§āĻāύāĨ¤
| Examination | Documentation |
|---|---|
| Blood Pressure | āϏāĻŽā§āĻāĻŦāϤ 110/80 mmHg |
| Pulse | āĻāϞā§āϞā§āĻ āύā§āĻ |
| Muscle Power | āĻāϞā§āϞā§āĻ āύā§āĻ |
| Muscle Tone | āĻāϞā§āϞā§āĻ āύā§āĻ |
| Deep Tendon Reflexes | āĻāϞā§āϞā§āĻ āύā§āĻ |
| Plantar Response | āĻāϞā§āϞā§āĻ āύā§āĻ |
| Cranial Nerve Examination | āĻāϞā§āϞā§āĻ āύā§āĻ |
| Gait | āĻāϞā§āϞā§āĻ āύā§āĻ |
| Sensory Examination | āĻāϞā§āϞā§āĻ āύā§āĻ |
Clinical Interpretation
āĻŦāϰā§āϤāĻŽāĻžāύ Functional Deficit āĻ āĻĨāĻŦāĻž Post-Stroke Spasticity āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻžāϰ āĻŽāϤ⧠Neurological Examination āĻĒāĻžāĻā§āĻž āϝāĻžā§āύāĻŋāĨ¤
ā§Ē. Investigations
āĻāĻ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āύāϤā§āύ āĻā§āύ⧠Laboratory āĻŦāĻž Imaging Investigation āϏā§āĻĒāώā§āĻāĻāĻžāĻŦā§ āĻĻā§āĻā§āĻž āĻšā§āύāĻŋāĨ¤
āĻāĻŋāĻāĻŋā§āϏāĻ CT Brain, MRI Brain, ECG āĻŦāĻž Lipid Profile āĻĻāĻŋā§ā§āĻā§āύâāĻāĻŽāύ āϤāĻĨā§āϝ āĻĒāĻžāĻā§āĻž āϝāĻžāĻā§āĻā§ āύāĻžāĨ¤
āύāĻŋāĻā§ āĻĒāϰāĻŦāϰā§āϤ⧠Clinical Assessment-āĻ āĻĒā§āϰā§ā§āĻāύā§ā§ āĻĒāϰā§āĻā§āώāĻž āĻāϞāĻžāĻĻāĻžāĻāĻžāĻŦā§ āĻāϞā§āĻāύāĻž āĻāϰāĻž āĻšā§ā§āĻā§āĨ¤
ā§Ģ. Advice â āĻāĻŋāĻāĻŋā§āϏāĻ āĻā§ āύāĻŋāϰā§āĻĻā§āĻļ āĻĻāĻŋā§ā§āĻā§āύ?
1. Physiotherapy
āĻŦāĻžāĻāϞāĻž: āĻĢāĻŋāĻāĻŋāĻāĻĨā§āϰāĻžāĻĒāĻŋāĨ¤
āϏā§āĻā§āϰā§āĻā§āϰ āĻĒāϰ⧠āĻĒā§āĻļāĻŋāϰ āĻĻā§āϰā§āĻŦāϞāϤāĻž, āĻāĻžāϰāϏāĻžāĻŽā§āϝāĻšā§āύāϤāĻž, āĻšāĻžāĻāĻāĻžāĻāϞāĻžāϰ āϏāĻŽāϏā§āϝāĻž āĻāĻŦāĻ āĻĻā§āύāύā§āĻĻāĻŋāύ āĻāĻžāϰā§āϝāĻā§āώāĻŽāϤāĻž āĻāύā§āύāϤ āĻāϰāĻžāϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ⧠āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āĻšā§āĨ¤
NICE NG236 (2023) āĻ āύā§āϝāĻžā§ā§ Stroke Rehabilitation āϰā§āĻā§āϰ āĻĒā§āϰā§ā§āĻāύ āĻ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ Functional Problem āĻ āύā§āϝāĻžā§ā§ āĻĒāϰāĻŋāĻāĻžāϞāĻŋāϤ āĻšāĻā§āĻž āĻāĻāĻŋāϤāĨ¤
2. Additional Bengali Advice
āĻĢāĻŋāĻāĻŋāĻāĻĨā§āϰāĻžāĻĒāĻŋāϰ āύāĻŋāĻā§ āĻāϰāĻ āĻāĻāĻāĻŋ āĻŦāĻžāĻāϞāĻž āύāĻŋāϰā§āĻĻā§āĻļ āϰā§ā§āĻā§āĨ¤ āϏā§āĻāĻŋāϰ āϏāĻŽā§āĻĒā§āϰā§āĻŖ āĻŦāĻžāĻā§āϝ āĻĒāϰāĻŋāώā§āĻāĻžāϰ āύā§āĨ¤
āĻā§āϞ āύāĻŋāϰā§āĻĻā§āĻļ āĻĻā§āĻā§āĻžāϰ āĻĒāϰāĻŋāĻŦāϰā§āϤ⧠āĻāĻāĻŋāĻā§ Unconfirmed āĻšāĻŋāϏā§āĻŦā§ āϰāĻžāĻāĻž āĻšā§ā§āĻā§āĨ¤
ā§Ŧ. Complete Drug Analysis â MedEx Verified
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āύāĻŋāĻā§āϰ āĻā§āĻāĻŋ āĻāώā§āϧ āĻĻā§āĻāĻž āϝāĻžāĻā§āĻā§āĨ¤
| No. | Prescribed Brand | Generic | Strength |
|---|---|---|---|
| 1 | Ecosprin | Aspirin | 75 mg |
| 2 | ATV | Atorvastatin Calcium | 10 mg |
| 3 | Algaba | Pregabalin | 50 mg |
| 4 | Reservix* | Aceclofenac | 100 mg |
| 5 | Losectil | Omeprazole | 20 mg |
| 6 | Beklo* | Baclofen | 5 mg |
ā§Ē āĻ ā§Ŧ āύāĻŽā§āĻŦāϰ āĻŦā§āϰā§āϝāĻžāύā§āĻĄā§āϰ āύāĻžāĻŽ āĻāĻā§āϰ āĻĒāĻžāĻ āĻ āύā§āϝāĻžā§ā§ āϏāĻŽā§āĻāĻžāĻŦā§āϝāĻāĻžāĻŦā§ āĻļāύāĻžāĻā§āϤ āĻāϰāĻž āĻšā§ā§āĻā§āĨ¤ āĻāώā§āϧā§āϰ āϏā§āĻā§āϰāĻŋāĻĒ āĻĻāĻŋā§ā§ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āĻāĻžāϞā§āĨ¤
Drug 1. Tab. Ecosprin 75 mg
Generic Name: Aspirin 75 mg
Bangladesh Brand: Ecosprin
Manufacturer: ACME Laboratories Ltd.
MedEx Therapeutic Class: Anti-platelet drugs.
Pharmacological Class: Irreversible Cyclooxygenase-1 Inhibitor; Antiplatelet Agent.
Unit Price: ā§ŗ0.80
Strip Price: ā§ŗ11.20 (ā§§ā§ĒāĻāĻŋ āĻā§āϝāĻžāĻŦāϞā§āĻ)āĨ¤
Other Available Strength: Ecosprin 81 mgāĨ¤
Use of Purpose
Aspirin āĻāĻŽ āĻŽāĻžāϤā§āϰāĻžā§ Thromboxane Aâ āĻā§āĻĒāĻžāĻĻāύ āĻŦāĻžāϧāĻžāĻā§āϰāϏā§āϤ āĻāϰ⧠Platelet Aggregation āĻāĻŽāĻžā§āĨ¤
āĻāĻāĻŋ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āĻšā§:
- Non-cardioembolic Ischemic Stroke-āĻāϰ Secondary PreventionāĨ¤
- Transient Ischemic Attack (TIA)āĨ¤
- Myocardial Infarction-āĻāϰ āĻĒāϰā§āĨ¤
- āύāĻŋāϰā§āĻŦāĻžāĻāĻŋāϤ Coronary Artery Disease-āĻāϰ āϰā§āĻā§āĻĻā§āϰ āĻā§āώā§āϤā§āϰā§āĨ¤
Why Prescribed in This Patient?
āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠Ischemic Stroke-āĻāϰ āĻĒāϰ⧠āĻĒā§āύāϰāĻžā§ āϰāĻā§āϤ āĻāĻŽāĻžāĻāĻāύāĻŋāϤ āϏā§āĻā§āϰā§āĻā§āϰ āĻā§āĻāĻāĻŋ āĻāĻŽāĻžāύā§āϰ āĻāύā§āϝāĨ¤
Clinical Assessment: Non-cardioembolic Stroke-āĻāϰ āĻā§āώā§āϤā§āϰ⧠āĻāĻĒāϝā§āĻā§āϤ Antiplatelet āĻšāĻŋāϏā§āĻŦā§ Aspirin āĻŦā§āϝāĻŦāĻšāĻžāϰ Guideline-supportedāĨ¤
āϤāĻŦā§ Cardioembolic Stroke, āĻŦāĻŋāĻļā§āώ āĻāϰ⧠Atrial Fibrillation āĻĨāĻžāĻāϞ⧠Anticoagulant āĻĒā§āϰā§ā§āĻāύ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Confidence: 0.95 â āϏāĻŽā§āĻāĻžāĻŦā§āϝ Prescribing IndicationāĨ¤
MedEx: Ecosprin 75 mg
Other BD Brands: Carva 75 mg, Cardoprin 75 mgāĨ¤
Drug 2. Tab. ATV 10 mg
Generic Name: Atorvastatin Calcium 10 mg
Brand Name: ATV
Manufacturer: Delta Pharma PLC.
MedEx Therapeutic Class: Other Anti-anginal & Anti-ischaemic drugs, Statins.
Pharmacological Class: HMG-CoA Reductase Inhibitor.
Unit Price: ā§ŗ5.00
Strip Price: ā§ŗ50.00 (ā§§ā§ĻāĻāĻŋ)āĨ¤
Other Available ATV Strengths: 20 mg, 40 mgāĨ¤
Use of Purpose
- HypercholesterolemiaāĨ¤
- Mixed DyslipidemiaāĨ¤
- Atherosclerotic Cardiovascular DiseaseāĨ¤
- Ischemic Stroke-āĻāϰ Secondary PreventionāĨ¤
- Cardiovascular Event Risk ReductionāĨ¤
Why Prescribed in This Patient?
āϏāĻŽā§āĻāĻŦāϤ āĻāĻŦāĻŋāώā§āϝāϤ⧠Ischemic Stroke āĻāĻŦāĻ āĻ āύā§āϝāĻžāύā§āϝ Atherosclerotic Cardiovascular Event-āĻāϰ āĻā§āĻāĻāĻŋ āĻāĻŽāĻžāύā§āϰ āĻāύā§āϝāĨ¤
Clinical Assessment
Atorvastatin 10 mg āĻāĻāĻāĻŋ Moderate-intensity Statin DoseāĨ¤
AHA/ASA 2021 Guideline āĻ āύā§āϝāĻžā§ā§ āĻ āύā§āĻ Ischemic Stroke āϰā§āĻā§āϰ āĻāύā§āϝ High-intensity Statin āĻĒā§āϰā§ā§āĻāύ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
āĻŦāĻŋāĻļā§āώāϤ Atherosclerotic Disease āĻĨāĻžāĻāϞ⧠LDL-C Target āϏāĻžāϧāĻžāϰāĻŖāϤ <70 mg/dLāĨ¤
āϰā§āĻā§āϰ LDL-C, Liver Function, āĻāώā§āϧā§āϰ āϏāĻšāύāĻļā§āϞāϤāĻž āĻāĻŦāĻ Stroke Etiology āύāĻž āĻā§āύ⧠āĻŦāϰā§āϤāĻŽāĻžāύ āĻĄā§āĻ āĻ āĻĒāϰā§āϝāĻžāĻĒā§āϤ āĻŦāϞāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
Confidence: 0.95
MedEx: ATV 10 mg
Other BD Brands: Atova 10 mg āĻ āĻ āύā§āϝāĻžāύā§āϝ Atorvastatin preparationsāĨ¤
Drug 3. Cap. ALGABA 50 mg â Corrected
āĻāĻāĻžāĻ āĻāĻĒāύāĻžāϰ āĻĻā§āĻā§āĻž āϏāĻāĻļā§āϧāύāĨ¤
Verified Drug Information
Brand Name: Algaba 50 mg
Generic Name: Pregabalin 50 mg
Manufacturer: Al-Madina Pharmaceuticals Ltd.
MedEx Therapeutic Class
Adjunct anti-epileptic drugs, Primary anti-epileptic drugs.
āĻāĻāĻŋ MedEx-āĻ āĻāϞā§āϞā§āĻāĻŋāϤ Therapeutic ClassificationāĨ¤ āϤāĻŦā§ āĻāώā§āϧāĻāĻŋāϰ āĻ āύā§āϝāϤāĻŽ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ Clinical Use āĻšāϞ⧠Neuropathic Pain ManagementāĨ¤
Pharmacological Class
Gabapentinoid Anticonvulsant; Îąâδ-subunit Ligand of Voltage-Gated Calcium Channels.
Pregabalin āϏāϰāĻžāϏāϰāĻŋ GABA-A āĻŦāĻž GABA-B Receptor Agonist āύā§āĨ¤
Unit & Strip Price
| Information | Details |
|---|---|
| Generic | Pregabalin |
| Strength | 50 mg |
| Unit Price | ā§ŗ12.00 |
| Strip Price | ā§ŗ120.00 |
| 30 Capsules | ā§ŗ360.00 |
| Other Algaba Strengths | 75 mg, 150 mg |
āĻāĻ āϤāĻĨā§āϝ āϏāϰāĻžāϏāϰāĻŋ MedEx āĻĨā§āĻā§ āϝāĻžāĻāĻžāĻ āĻāϰāĻž āĻšā§ā§āĻā§āĨ¤
Use of Purpose
Pregabalin āĻŦāĻŋāĻāĻŋāύā§āύ āϰā§āĻā§ āĻŦā§āϝāĻŦāĻšā§āϤ āĻšā§:
- Neuropathic Pain â āϏā§āύāĻžā§ā§āĻāύāĻŋāϤ āĻŦā§āϝāĻĨāĻžāĨ¤
- Diabetic Peripheral Neuropathy â āĻĄāĻžā§āĻžāĻŦā§āĻāĻŋāϏā§āϰ āĻāĻžāϰāĻŖā§ āϏā§āύāĻžā§ā§āϰ āĻŦā§āϝāĻĨāĻžāĨ¤
- Postherpetic Neuralgia â āĻšāĻžāϰāĻĒāĻŋāϏ āĻā§āϏā§āĻāĻžāϰā§āϰ āĻĒāϰ⧠āϏā§āύāĻžā§ā§āĻāύāĻŋāϤ āĻŦā§āϝāĻĨāĻžāĨ¤
- Fibromyalgia â āĻĻā§āϰā§āĻāϏā§āĻĨāĻžā§ā§ āĻŦā§āϝāĻžāĻĒāĻ āĻŦā§āϝāĻĨāĻžāϰ āĻāĻāĻāĻŋ āĻ āĻŦāϏā§āĻĨāĻžāĨ¤
- Partial-onset Seizures â āĻ āύā§āϝāĻžāύā§āϝ āĻāĻĒāϝā§āĻā§āϤ āĻāώā§āϧā§āϰ āϏāĻā§āĻā§ āϏāĻšāĻžā§āĻ āĻāĻŋāĻāĻŋā§āϏāĻžāĨ¤
- Central Neuropathic Pain â āύāĻŋāϰā§āĻŦāĻžāĻāĻŋāϤ āϰā§āĻā§āϰ āĻā§āύā§āĻĻā§āϰā§ā§ āϏā§āύāĻžā§ā§āϤāύā§āϤā§āϰā§āϰ āĻā§āώāϤāĻŋāϰ āĻāĻžāϰāĻŖā§ āĻŦā§āϝāĻĨāĻžāĨ¤
Why Doctor Prescribed Algaba in This Patient?
āĻāĻŽāĻžāϰ Working Clinical Interpretation āĻ āύā§āϝāĻžā§ā§ āϏāĻŦāĻā§ā§ā§ āϝā§āĻā§āϤāĻŋāϏāĻāĻāϤ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āĻšāϞā§:
Suspected Post-Stroke Neuropathic Pain.
āĻŦāĻžāĻāϞāĻž: āϏā§āĻā§āϰā§āĻā§āϰ āĻĒāϰ āϏā§āύāĻžā§ā§āĻāύāĻŋāϤ āĻŦā§āϝāĻĨāĻžāϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻžāĨ¤
āϏā§āĻā§āϰā§āĻā§āϰ āĻĒāϰ⧠āĻāĻŋāĻā§ āϰā§āĻā§āϰ āĻŦā§āϝāĻĨāĻž āĻšāϤ⧠āĻĒāĻžāϰā§, āϝāĻž āϏāĻžāϧāĻžāϰāĻŖ āĻĒā§āĻļāĻŋ āĻŦāĻž āĻ āϏā§āĻĨāĻŋāϏāύā§āϧāĻŋāϰ āĻŦā§āϝāĻĨāĻž āĻĨā§āĻā§ āĻāĻŋāύā§āύāĨ¤
āϝā§āĻŽāύ:
- āĻā§āĻŦāĻžāϞāĻžāĻĒā§ā§āĻž āϧāϰāύā§āϰ āĻŦā§āϝāĻĨāĻžāĨ¤
- āĻŦāĻŋāĻĻā§āϝā§ā§āϏā§āĻĒā§āώā§āĻ āĻšāĻā§āĻžāϰ āĻŽāϤ⧠āĻŦā§āϝāĻĨāĻžāĨ¤
- āϏā§āĻĒāϰā§āĻļā§ āĻ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻŦā§āϝāĻĨāĻžāĨ¤
- āϏā§āĻ āĻĢā§āĻāĻžāϰ āĻŽāϤ⧠āĻ āύā§āĻā§āϤāĻŋāĨ¤
- āĻāĻā§āϰāĻžāύā§āϤ āĻ āĻāĻļā§ āĻ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ SensationāĨ¤
āϤāĻŦā§ āĻāĻ āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠āĻāϏāĻŦ āĻāĻĒāϏāϰā§āĻā§āϰ āĻāĻĒāϏā§āĻĨāĻŋāϤāĻŋ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āĻšā§āύāĻŋāĨ¤
āϤāĻžāĻ āĻļā§āϧ⧠Algaba āϞā§āĻāĻž āĻāĻā§ āĻŦāϞ⧠Central Post-Stroke Pain Syndrome āύāĻŋāĻļā§āĻāĻŋāϤ Diagnosis āĻšāĻŋāϏā§āĻŦā§ āϞā§āĻāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
Guideline Support
NICE CG173 āĻ āύā§āϝāĻžā§ā§ Neuropathic Pain-āĻāϰ āĻĒā§āϰāĻžāĻĨāĻŽāĻŋāĻ āĻāώā§āϧā§āϰ āĻŦāĻŋāĻāϞā§āĻĒāĻā§āϞā§āϰ āĻŽāϧā§āϝ⧠āϰā§ā§āĻā§ Pregabalin, Gabapentin, Duloxetine āĻ AmitriptylineāĨ¤
Clinical Precautions
Pregabalin-āĻāϰ āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž āĻšāϤ⧠āĻĒāĻžāϰā§:
- Dizziness
- Somnolence
- Peripheral Edema
- Blurred Vision
- Balance Impairment
āĻŦāĻŋāĻļā§āώ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ: Pregabalin āĻāĻŦāĻ Baclofen āĻāĻāϏāĻā§āĻā§ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧠āĻā§āĻŽāĻā§āĻŽ āĻāĻžāĻŦ, āĻŽāĻžāĻĨāĻž āĻā§āϰāĻž āĻ āĻĒā§ā§ āϝāĻžāĻā§āĻžāϰ āĻā§āĻāĻāĻŋ āĻŦāĻžā§āϤ⧠āĻĒāĻžāϰā§āĨ¤
Kidney Function āĻ āύā§āϝāĻžā§ā§ Pregabalin-āĻāϰ āĻĄā§āĻ āϏāĻŽāύā§āĻŦā§ āĻĒā§āϰā§ā§āĻāύ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
āĻ āĻāĻžā§āĻž āĻĻā§āϰā§āĻāĻĻāĻŋāύ āϏā§āĻŦāύā§āϰ āĻĒāϰ⧠āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āύāĻŋāϰā§āĻĻā§āĻļ āĻāĻžā§āĻž āĻšāĻ āĻžā§ āĻŦāύā§āϧ āĻāϰāĻž āĻāĻāĻŋāϤ āύā§āĨ¤
Bangladesh Available Brands
| Brand | Generic | Strength |
|---|---|---|
| Algaba | Pregabalin | 50 mg |
| Nervalin | Pregabalin | 50 mg |
| Neurolin | Pregabalin | 50 mg |
| Prelin | Pregabalin | 50 mg |
| Neurica | Pregabalin | 50 mg |
| Neurovan | Pregabalin | 50 mg |
āĻāϏāĻŦ āĻāĻāĻ Generic-āĻāϰ āĻāĻĻāĻžāĻšāϰāĻŖ; āĻāĻŋāĻāĻŋā§āϏāĻžāĻāϤāĻāĻžāĻŦā§ āϏā§āĻŦā§āĻāĻā§āϰāĻŋā§āĻāĻžāĻŦā§ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ āĻĒāϰāĻŋāĻŦāϰā§āϤāύā§āϰ āύāĻŋāϰā§āĻĻā§āĻļ āύā§āĨ¤
MedEx Direct Link
Confidence:
- Drug Identification: 1.00
- Suspected Neuropathic Pain Indication: 0.60
- Confirmed Central Post-Stroke Pain Diagnosis: āĻĒā§āϰāĻŽāĻžāĻŖ āĻ āĻĒāϰā§āϝāĻžāĻĒā§āϤ
Drug 4. Tab. Reservix 100 mg â Probable Identification
Generic Name: Aceclofenac 100 mg
Brand Name: Reservix
Manufacturer: Incepta Pharmaceuticals Ltd.
MedEx Therapeutic Class: Drugs for Osteoarthritis, Drugs used for Rheumatoid Arthritis, Non-steroidal Anti-inflammatory Drugs (NSAIDs).
Pharmacological Class: Phenylacetic Acid Derivative NSAID; Cyclooxygenase Inhibitor.
Unit Price: ā§ŗ5.70
Strip Price: ā§ŗ57.00āĨ¤
Other Available Strength: Reservix SR 200 mgāĨ¤
Use of Purpose
- OsteoarthritisāĨ¤
- Rheumatoid ArthritisāĨ¤
- Ankylosing SpondylitisāĨ¤
- Musculoskeletal PaināĨ¤
- Inflammatory PaināĨ¤
Why Prescribed in This Patient?
āϏāĻŽā§āĻāĻŦāϤ āĻŦā§āϝāĻĨāĻž āĻŦāĻž āĻĒā§āϰāĻĻāĻžāĻš āĻāĻŽāĻžāύā§āϰ āĻāύā§āϝāĨ¤
āĻāĻŋāύā§āϤ⧠āϰā§āĻā§āϰ āĻŦā§āϝāĻĨāĻžāϰ āĻā§āϏ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āϏā§āĻĒāώā§āĻāĻāĻžāĻŦā§ āĻāϞā§āϞā§āĻ āύā§āĻāĨ¤
â ī¸ Important Safety Concern
āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠Ischemic Stroke āĻĨāĻžāĻāĻž āϰā§āĻā§āϰ āĻāύā§āϝ Aceclofenac āĻ āϤā§āϝāύā§āϤ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ Medication Review-āĻāϰ āĻŦāĻŋāώā§āĨ¤
āϝā§āĻā§āϤāϰāĻžāĻā§āϝā§āϰ MHRA āĻ āύā§āϝāĻžā§ā§ Established Cerebrovascular Disease-āĻ Aceclofenac contraindicatedāĨ¤
āĻ āĻāĻžā§āĻž Aspirin-āĻāϰ āϏāĻā§āĻā§ NSAID āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāϞ⧠Gastrointestinal Bleeding-āĻāϰ āĻā§āĻāĻāĻŋāĻ āĻŦā§āĻĻā§āϧāĻŋ āĻĒā§āϤ⧠āĻĒāĻžāϰā§āĨ¤
āϏā§āϤāϰāĻžāĻ āĻāώā§āϧāĻāĻŋ āϏāϤā§āϝāĻŋāĻ Reservix āĻāĻŋ āύāĻž āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰā§, āĻĒāϰāĻŦāϰā§āϤ⧠āĻĄā§āĻā§āϰ āĻāĻā§ āĻĒā§āϰā§āϏāĻā§āϰāĻžāĻāĻŦāĻŋāĻ āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āϏāĻā§āĻā§ āĻāϰ āĻāĻĒāϝā§āĻā§āϤāϤāĻž āϝāĻžāĻāĻžāĻ āĻāϰāĻž āĻāĻāĻŋāϤāĨ¤
āĻāĻāĻŋ Stroke Prevention-āĻāϰ āĻāώā§āϧ āύā§āĨ¤
MedEx: Reservix 100 mg
Alternative BD Brands: Acefenac, Acenac, PreservināĨ¤
Drug 5. Cap. Losectil 20 mg
Generic Name: Omeprazole 20 mg
Manufacturer: Eskayef Pharmaceuticals Ltd.
MedEx Therapeutic Class: Proton Pump Inhibitor.
Pharmacological Class: Gastric Hâē/Kâē-ATPase Inhibitor.
Unit Price: ā§ŗ5.00
Strip Price: ā§ŗ50.00 āĻ
āĻĨāĻŦāĻž ā§ŗ60.00, āĻĒā§āϝāĻžāĻā§āϰ āĻāĻāĻžāϰ āĻ
āύā§āϝāĻžā§ā§āĨ¤
Other Available Strengths: 10 mg, 40 mgāĨ¤
Use of Purpose
- GERDāĨ¤
- Peptic Ulcer DiseaseāĨ¤
- Gastritis-associated acid symptomsāĨ¤
- NSAID-associated Gastric UlcerāĨ¤
- āύāĻŋāϰā§āĻŦāĻžāĻāĻŋāϤ āϰā§āĻā§āϰ GastroprotectionāĨ¤
Why Doctor Prescribed?
āϏāĻŽā§āĻāĻŦāϤ Aspirin āĻāĻŦāĻ Painkiller āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āϏāĻŽā§ āĻĒāĻžāĻāϏā§āĻĨāϞā§āϰ āĻ ā§āϝāĻžāϏāĻŋāĻĄāĻāύāĻŋāϤ āϏāĻŽāϏā§āϝāĻž āĻŦāĻž Gastrointestinal Ulcer-āĻāϰ āĻā§āĻāĻāĻŋ āĻāĻŽāĻžāύā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝā§āĨ¤
Clinical Limitation: āϰā§āĻā§āϰ āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠Gastric Ulcer āĻŦāĻž GI Bleeding-āĻāϰ āĻāϤāĻŋāĻšāĻžāϏ āĻāĻžāύāĻž āύā§āĻāĨ¤
MedEx: Losectil 20 mg
Alternative BD Brand: Seclo 20 mgāĨ¤
Drug 6. Tab. Beklo 5 mg â Probable Identification
Generic Name: Baclofen 5 mg
Manufacturer: Opsonin Pharma Ltd.
MedEx Therapeutic Class: Centrally acting Skeletal Muscle Relaxants.
Pharmacological Class: GABA-B Receptor Agonist; Centrally Acting Antispastic Agent.
Unit Price: ā§ŗ5.50
Strip Price: ā§ŗ77.00āĨ¤
Other Available Strengths: 10 mg, 25 mgāĨ¤ āĻāĻāĻžā§āĻž Oral Solution āϰā§ā§āĻā§āĨ¤
Use of Purpose
- SpasticityāĨ¤
- Muscle SpasmāĨ¤
- Multiple Sclerosis-associated SpasticityāĨ¤
- Spinal Cord Injury-associated SpasticityāĨ¤
- āύāĻŋāϰā§āĻŦāĻžāĻāĻŋāϤ Post-Stroke SpasticityāĨ¤
Why Doctor Prescribed?
āϏāĻŽā§āĻāĻŦāϤ āϏā§āĻā§āϰā§āĻā§āϰ āĻĒāϰ⧠āĻŽāĻžāĻāϏāĻĒā§āĻļāĻŋāϤ⧠āĻ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻāĻžāύ āĻŦāĻž Spasticity āĻāĻŽāĻžāύā§āϰ āĻāύā§āϝāĨ¤
āϤāĻŦā§ āϰā§āĻā§āϰ Muscle Tone, Reflexes āĻāĻŦāĻ Modified Ashworth Scale-āĻāϰ āĻĢāϞ āĻĒāĻžāĻā§āĻž āϝāĻžā§āύāĻŋāĨ¤
Clinical Assessment
NICE NG236 (2023) āĻ āύā§āϝāĻžā§ā§ Generalised Post-Stroke Spasticity āĻĨāĻžāĻāϞ⧠Oral Baclofen āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāĻž āϝāĻžā§, āϤāĻŦā§ adverse effects āύāĻŋāĻŦāĻŋā§āĻāĻžāĻŦā§ āĻĒāϰā§āϝāĻŦā§āĻā§āώāĻŖ āĻāϰāĻž āĻĒā§āϰā§ā§āĻāύāĨ¤
Baclofen āĻā§āĻŽāĻā§āĻŽ āĻāĻžāĻŦ, āĻŽāĻžāĻĨāĻž āĻā§āϰāĻž āĻāĻŦāĻ Muscle Weakness āϏā§āώā§āĻāĻŋ āĻāϰāϤ⧠āĻĒāĻžāϰā§āĨ¤ āϏā§āĻā§āϰā§āĻā§āϰ āϰā§āĻā§āϰ āĻŽāϧā§āϝ⧠āĻāϰ āϏāĻšāύāĻļā§āϞāϤāĻž āĻāĻŽ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
MedEx: Beklo 5 mg
Confidence:
- Drug Identification: 0.85
- Possible Spasticity-related Indication: 0.70
ā§. Medication Summary â āĻā§āύ āĻā§āύ āĻāώā§āϧ?
| Drug | Main Purpose in This Case | Assessment |
|---|---|---|
| Ecosprin 75 | āĻĒā§āύāϰāĻžā§ Ischemic Stroke āĻĒā§āϰāϤāĻŋāϰā§āϧ | āĻāĻĒāϝā§āĻā§āϤ Stroke Subtype āĻšāϞ⧠āϝā§āĻā§āϤāĻŋāϏāĻāĻāϤ |
| ATV 10 | LDL āĻāĻŽāĻžāύ⧠āĻ Vascular Risk Reduction | Statin Intensity Review āĻĒā§āϰā§ā§āĻāύ |
| Algaba 50 | āϏāĻŽā§āĻāĻžāĻŦā§āϝ Neuropathic Pain | āĻŦā§āϝāĻĨāĻžāϰ History āĻ Examination āĻĒā§āϰā§ā§āĻāύ |
| Reservix 100 | āϏāĻŽā§āĻāĻžāĻŦā§āϝ Musculoskeletal Pain | Stroke History āĻĨāĻžāĻāĻžā§ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ Safety Concern |
| Losectil 20 | Gastric Acid Suppression / Gastroprotection | Indication āĻ Duration Review |
| Beklo 5 | āϏāĻŽā§āĻāĻžāĻŦā§āϝ Spasticity Control | Tone āĻ Functional Assessment āĻĒā§āϰā§ā§āĻāύ |
āύā§āĻ: āĻāώā§āϧā§āϰ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻĻā§āĻā§ āϰā§āĻā§āϰ āϏāĻŦ āϰā§āĻ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āϝāĻžā§ āύāĻžāĨ¤ Prescription Indication āĻāĻŦāĻ Confirmed Diagnosis āĻāĻ āĻŦāĻŋāώ⧠āύā§āĨ¤
āĻšāĻžāϤā§āϰ āϞā§āĻāĻžā§ āĻāĻŋāĻā§ āĻāώā§āϧā§āϰ āϏā§āĻŦāύā§āϰ āϏāĻŽā§ āĻŦā§āĻāĻž āĻā§āϞā§āĻ āϏāĻŦ āĻĄā§āĻā§āϰ Frequency āĻ Duration āύāĻŋāĻļā§āĻāĻŋāϤ āύā§āĨ¤ āϤāĻžāĻ āĻā§āϞāĻāĻžāĻŦā§ āϏāĻŽā§āĻĒā§āϰā§āĻŖ Dosage Schedule āϤā§āϰāĻŋ āĻāϰāĻž āĻšā§āύāĻŋāĨ¤
ā§Ž. Clinical Definition & Pathophysiology
Ischemic Stroke
āĻŽāϏā§āϤāĻŋāώā§āĻā§āϰ āĻā§āύ⧠āĻ āĻāĻļā§ āϰāĻā§āϤ āϏāϰāĻŦāϰāĻžāĻš āĻšāĻ āĻžā§ āĻāĻŽā§ āĻā§āϞ⧠āĻŦāĻž āĻŦāύā§āϧ āĻšā§ā§ āĻā§āϞ⧠Neurological Injury āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
āĻĒā§āϰāϧāĻžāύ Mechanism:
- Large Artery AtherosclerosisāĨ¤
- Small Vessel OcclusionāĨ¤
- CardioembolismāĨ¤
- āĻ āύā§āϝāĻžāύā§āϝ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻ āĻĨāĻŦāĻž āĻ āύāĻŋāϰā§āϧāĻžāϰāĻŋāϤ āĻāĻžāϰāĻŖāĨ¤
āĻĻā§āϰā§āĻāĻŽā§ā§āĻžāĻĻāĻŋ HTN Small Vessel Disease āĻāĻŦāĻ Atherosclerosis-āĻāϰ āĻā§āĻāĻāĻŋ āĻŦā§āĻĻā§āϧāĻŋ āĻāϰāϤ⧠āĻĒāĻžāϰā§āĨ¤
Post-Stroke Complications
āϰā§āĻā§āϰ Stroke-āĻāϰ āĻ āĻŦāϏā§āĻĨāĻžāύ āĻ āϤā§āĻŦā§āϰāϤāĻžāϰ āĻāĻĒāϰ āύāĻŋāϰā§āĻāϰ āĻāϰ⧠āĻĻā§āĻāĻž āĻĻāĻŋāϤ⧠āĻĒāĻžāϰā§:
- Hemiparesis
- Hemiplegia
- Dysphasia/Aphasia
- Sensory Impairment
- Gait Disturbance
- Spasticity
- Central Post-Stroke Pain
āĻāĻ āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠āĻā§āύāĻāĻŋ āĻŦāϰā§āϤāĻŽāĻžāύ⧠āĻāĻā§, āϤāĻž Physical Examination āĻāĻžā§āĻž āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
⧝. My Clinical Working Diagnosis
A. Documented Diagnoses
1. History of Ischemic Stroke
āĻŦāĻžāĻāϞāĻž: āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āĻāϏā§āĻā§āĻŽāĻŋāĻ āϏā§āĻā§āϰā§āĻā§āϰ āĻāϤāĻŋāĻšāĻžāϏāĨ¤
2. History of Hypertension
āĻŦāĻžāĻāϞāĻž: āĻāĻā§āĻ āϰāĻā§āϤāĻāĻžāĻĒā§āϰ āĻāϤāĻŋāĻšāĻžāϏāĨ¤
B. Conditions Requiring Confirmation
3. Possible Post-Stroke Neuropathic Pain
āĻŦāĻžāĻāϞāĻž: āϏā§āĻā§āϰā§āĻ-āĻĒāϰāĻŦāϰā§āϤ⧠āϏā§āύāĻžā§ā§āĻāύāĻŋāϤ āĻŦā§āϝāĻĨāĻžāϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻžāĨ¤
āĻāĻāĻŋ Algaba āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻāĻāĻŋ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻŦā§āϝāĻžāĻā§āϝāĻž; āύāĻŋāĻļā§āĻāĻŋāϤ Diagnosis āύā§āĨ¤
4. Possible Post-Stroke Spasticity
āĻŦāĻžāĻāϞāĻž: āϏā§āĻā§āϰā§āĻ-āĻĒāϰāĻŦāϰā§āϤ⧠āĻŽāĻžāĻāϏāĻĒā§āĻļāĻŋāϰ āĻ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻāĻžāύā§āϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻžāĨ¤
āĻāĻāĻŋ Beklo āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻŦā§āϝāĻžāĻā§āϝāĻž; āύāĻŋāĻļā§āĻāĻŋāϤ Diagnosis āύā§āĨ¤
Diagnostic Confidence
| Assessment | Confidence | Evidence |
|---|---|---|
| Previous Ischemic Stroke documented | 0.98 | āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āϞā§āĻāĻž |
| Hypertension documented | 0.99 | āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āϞā§āĻāĻž |
| Current Residual Neurological Deficit | 0.60 | Rehabilitation advice, āĻāĻŋāύā§āϤ⧠Examination āύā§āĻ |
| Neuropathic Pain | 0.60 | Pregabalin prescribed |
| Spasticity | 0.70 | Baclofen prescribed |
| Specific Stroke Etiology | āύāĻŋāϰā§āϧāĻžāϰāĻŖāϝā§āĻā§āϝ āύ⧠| Imaging āĻ Cardiac Workup āύā§āĻ |
āĻāĻ Confidence Score-āĻā§āϞ⧠āύāĻĨāĻŋāĻĒāĻžāĻ āĻ Clinical Interpretation-āĻāϰ āĻāύā§āĻŽāĻžāύāĻŋāĻ āύāĻŋāĻļā§āĻā§āϤāĻž āĻĒā§āϰāĻāĻžāĻļ āĻāϰā§; āϰā§āĻ āύāĻŋāϰā§āĻŖā§ā§āϰ āĻĒāϰā§āĻā§āώāĻžā§ āĻĒā§āϰāĻŽāĻžāĻŖāĻŋāϤ Probability āύā§āĨ¤
ā§§ā§Ļ. Doctor’s Dx vs My Working Dx
| Doctor’s Documentation | My Assessment | Comparison |
|---|---|---|
| HTN | History of Hypertension | Similar |
| Ischemic Stroke | History of Ischemic Stroke | Similar |
| Neuropathic Pain | Possible | Doctor āϏāϰāĻžāϏāϰāĻŋ āϞā§āĻā§āύāύāĻŋ |
| Spasticity | Possible | Doctor āϏāϰāĻžāϏāϰāĻŋ āϞā§āĻā§āύāύāĻŋ |
Final Justification
āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āύāĻĨāĻŋāĻā§āĻā§āϤ āĻŽā§āϞ āϰā§āĻā§āϰ āϏāĻā§āĻā§ āĻāĻŽāĻžāϰ Working Diagnosis āϏāĻžāĻŽāĻā§āĻāϏā§āϝāĻĒā§āϰā§āĻŖāĨ¤
āϤāĻŦā§ Algaba āĻ Beklo āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻžāϰāĻŖā§ Neuropathic Pain āĻāĻŦāĻ Spasticity-āĻāϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāĻž āĻšā§ā§āĻā§āĨ¤
āĻāĻ āĻĻā§āĻāĻŋ āϏāĻŽāϏā§āϝāĻž āύāĻŋāĻļā§āĻāĻŋāϤ āύāĻž āĻšāĻā§āĻž āĻĒāϰā§āϝāύā§āϤ Diagnosis-āĻ āύāĻŋāĻļā§āĻāĻŋāϤ āϰā§āĻ āĻšāĻŋāϏā§āĻŦā§ āϞā§āĻāĻž āĻāĻāĻŋāϤ āύā§āĨ¤
ā§§ā§§. Differential Diagnosis
āĻŦāϰā§āϤāĻŽāĻžāύ āĻāĻĒāϏāϰā§āĻ āĻ āύā§āϝāĻžā§ā§ āĻŦāĻŋāĻŦā§āĻāύāĻžā§ āϰāĻžāĻāϤ⧠āĻšāĻŦā§:
| Differential Diagnosis | Clinical Clue |
|---|---|
| Residual Deficit Following Previous Stroke | āĻĒā§āϰā§āύ⧠āϏā§āĻĨāĻžā§ā§ āĻĻā§āϰā§āĻŦāϞāϤāĻž |
| Recurrent Ischemic Stroke | āύāϤā§āύ Neurological Deficit |
| Central Post-Stroke Pain | Stroke-āĻāϰ āĻĒāϰ⧠Neuropathic Pain |
| Post-Stroke Spasticity | Increased Muscle Tone, Hyperreflexia |
| Peripheral Neuropathy | Peripheral Sensory Symptoms |
| Cervical Myelopathy | Gait Problem, Hyperreflexia, Limb Weakness |
āύāϤā§āύ āĻĻā§āϰā§āĻŦāϞāϤāĻž āĻĨāĻžāĻāϞ⧠āĻĒā§āϰāĻĨāĻŽā§āĻ Acute Stroke Exclusion āĻāϰā§āϰāĻŋāĨ¤
⧧⧍. Recommended Investigations
āĻāĻā§āϞ⧠āύāϤā§āύ Clinical Recommendation; āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āϞā§āĻāĻž āĻĒāϰā§āĻā§āώāĻžāϰ āϤāĻžāϞāĻŋāĻāĻž āύā§āĨ¤
| Investigation | Purpose |
|---|---|
| Previous CT/MRI Brain Review | Stroke Type āĻ Lesion Location |
| MRI Brain | āύāϤā§āύ Stroke āĻŦāĻž Diagnosis āĻ āύāĻŋāĻļā§āĻāĻŋāϤ āĻšāϞ⧠|
| ECG | Atrial Fibrillation |
| Holter Monitoring | Occult AF āϏāύā§āĻĻā§āĻš āĻšāϞ⧠|
| Echocardiography | Cardioembolic Source, āϝāĻāύ āύāĻŋāϰā§āĻĻā§āĻļāĻŋāϤ |
| Lipid Profile | LDL-C āĻ Statin Response |
| HbA1c | Diabetes Screening |
| Serum Creatinine/eGFR | Renal Function āĻ Drug-dose Review |
| Serum Electrolytes | Metabolic Assessment |
| CBC | Anaemia āĻ Platelet Evaluation |
| LFT | Statin-related Clinical Monitoring, āϝāĻāύ āĻĒā§āϰā§ā§āĻāύ |
| Carotid/Vascular Imaging | Stroke Etiology āĻ āύā§āϝāĻžā§ā§ |
Neurological Examination
Muscle Power, Tone, Sensation, Reflexes, Plantar Response, Coordination, Gait āĻ Functional Assessment āĻāϰāĻž āĻĒā§āϰā§ā§āĻāύāĨ¤
Spasticity āĻĨāĻžāĻāϞ⧠Modified Ashworth Scale āĻāĻŦāĻ Functional Limitation āύāĻĨāĻŋāĻā§āĻā§āϤ āĻāϰāĻž āϝā§āϤ⧠āĻĒāĻžāϰā§āĨ¤
ā§§ā§Š. Bangladesh Doctors Commonly Use Which Drugs?
āϰā§āĻā§āϰ āϧāϰāύ āĻ Clinical Indication āĻ āύā§āϝāĻžā§ā§ āĻŦāĻžāĻāϞāĻžāĻĻā§āĻļā§ āĻĒā§āϰāĻāϞāĻŋāϤ āĻāĻŋāĻā§ Generic āĻ Brand-āĻāϰ āĻāĻĻāĻžāĻšāϰāĻŖ āύāĻŋāĻā§ āĻĻā§āĻā§āĻž āĻšāϞā§āĨ¤
āĻāĻā§āϞ⧠āϰā§āĻā§āϰ āĻāύā§āϝ āύāϤā§āύ Prescription āύā§āĨ¤ āϏāĻŦ āĻāώā§āϧ āĻāĻāϏāĻā§āĻā§ āĻĻā§āĻā§āĻžāϰ āϤāĻžāϞāĻŋāĻāĻžāĻ āύā§āĨ¤
| No. | Generic | Bangladesh Brand Example | Clinical Indication |
|---|---|---|---|
| 1 | Aspirin | Ecosprin, Carva | Non-cardioembolic Stroke Prevention |
| 2 | Clopidogrel | Clopid, Clognil | āĻŦāĻŋāĻāϞā§āĻĒ Antiplatelet |
| 3 | Atorvastatin | ATV, Atova | LDL Reduction |
| 4 | Rosuvastatin | Rosuva, Rosutin | LDL Reduction |
| 5 | Ezetimibe | āĻŦāĻŋāĻāĻŋāύā§āύ BD Brand | āĻĒā§āϰā§ā§āĻāύ āĻ āύā§āϝāĻžā§ā§ āĻ āϤāĻŋāϰāĻŋāĻā§āϤ LDL Reduction |
| 6 | Amlodipine | Amdocal | Hypertension, āĻāĻĒāϝā§āĻā§āϤ āϰā§āĻā§ |
| 7 | Pregabalin | Algaba, Neurolin | Neuropathic Pain |
| 8 | Gabapentin | āĻŦāĻŋāĻāĻŋāύā§āύ BD Brand | Neuropathic Pain |
| 9 | Duloxetine | āĻŦāĻŋāĻāĻŋāύā§āύ BD Brand | Neuropathic Pain |
| 10 | Amitriptyline | āĻŦāĻŋāĻāĻŋāύā§āύ BD Brand | Neuropathic Pain |
| 11 | Baclofen | Beklo | āύāĻŋāϰā§āĻŦāĻžāĻāĻŋāϤ Generalised Spasticity |
| 12 | Omeprazole | Losectil, Seclo | āĻāĻĒāϝā§āĻā§āϤ āĻā§āώā§āϤā§āϰ⧠Gastroprotection |
AHA/ASA Stroke Prevention Guideline āĻāĻŦāĻ NICE Neuropathic Pain Guideline āĻ āύā§āϝāĻžā§ā§ āĻāώā§āϧ āύāĻŋāϰā§āĻŦāĻžāĻāύ āϰā§āĻā§āϰ Stroke Subtype, Associated Conditions, Contraindications āĻāĻŦāĻ Treatment Response-āĻāϰ āĻāĻĒāϰ āύāĻŋāϰā§āĻāϰ āĻāϰā§āĨ¤
ā§§ā§Ē. Management / Treatment Review
A. Stroke Secondary Prevention
Non-cardioembolic Ischemic Stroke āĻšāϞ⧠āĻĻā§āϰā§āĻāĻŽā§ā§āĻžāĻĻāĻŋ Single Antiplatelet Therapy āĻāĻĒāϝā§āĻā§āϤ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Atrial Fibrillation-related Stroke āĻšāϞ⧠āĻāĻĒāϝā§āĻā§āϤ āĻĒāϰāĻŋāϏā§āĻĨāĻŋāϤāĻŋāϤ⧠Anticoagulation āĻĒā§āϰā§ā§āĻāύ āĻšā§āĨ¤
Aspirin āĻāĻŦāĻ Clopidogrel āĻĻā§āϰā§āĻāĻŽā§ā§āĻžāĻĻā§ āĻāĻāϏāĻā§āĻā§ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ āϧāĻŋāĻāĻžāĻāĻļ Stroke āϰā§āĻā§āϰ āĻāύā§āϝ āύāĻŋā§āĻŽāĻŋāϤ āϏā§āĻĒāĻžāϰāĻŋāĻļ āĻāϰāĻž āĻšā§ āύāĻžāĨ¤
B. Blood Pressure Control
Neurologically stable Stroke Survivor-āĻāϰ āĻŽāϧā§āϝ⧠āĻ āϧāĻŋāĻāĻžāĻāĻļā§āϰ āĻāύā§āϝ Target BP:
<130/80 mmHg
āϤāĻŦā§ āϰā§āĻā§āϰ āĻ āĻŦāϏā§āĻĨāĻž, āϏāĻšāύāĻļā§āϞāϤāĻž āĻāĻŦāĻ āĻ āύā§āϝāĻžāύā§āϝ āϰā§āĻ āĻ āύā§āϝāĻžā§ā§ āĻŦā§āϝāĻā§āϤāĻŋāĻāϤāĻāĻžāĻŦā§ āϞāĻā§āώā§āϝ āύāĻŋāϰā§āϧāĻžāϰāĻŖ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āĻāϞāĻžāĻĻāĻž Antihypertensive Drug āĻā§āĻā§ āĻĒā§āĻā§ āύāĻžāĨ¤ āϰā§āĻā§ āĻāĻā§ āĻĨā§āĻā§ āĻā§āύ⧠BP Medicine āĻāĻžāĻā§āĻā§āύ āĻāĻŋ āύāĻž āϤāĻž āϝāĻžāĻāĻžāĻ āĻāϰāĻž āĻĒā§āϰā§ā§āĻāύāĨ¤
C. Lipid Management
Lipid Profile āĻ Stroke Etiology āĻĒāϰā§āϝāĻžāϞā§āĻāύāĻž āĻāϰ⧠āĻŦāϰā§āϤāĻŽāĻžāύ Atorvastatin 10 mg āϝāĻĨā§āώā§āĻ āĻāĻŋ āύāĻž āĻŽā§āϞā§āϝāĻžā§āύ āĻĒā§āϰā§ā§āĻāύāĨ¤
āύāĻŋāĻā§ āĻĨā§āĻā§ Statin Dose āĻĒāϰāĻŋāĻŦāϰā§āϤāύ āĻāϰāĻž āĻāĻāĻŋāϤ āύā§āĨ¤
D. Neuropathic Pain Assessment
Algaba-āĻāϰ āĻĒā§āϰā§ā§āĻāύā§ā§āϤāĻž āĻŽā§āϞā§āϝāĻžā§āύā§āϰ āĻāύā§āϝ Pain Distribution, Character, Severity, Sensory Abnormality āĻ Functional Impact āĻāĻžāύāĻž āĻĒā§āϰā§ā§āĻāύāĨ¤
E. Spasticity Rehabilitation
Baclofen-āĻāϰ āϏāĻŽā§āĻāĻžāĻŦā§āϝ Benefit āĻ Risk āĻŽā§āϞā§āϝāĻžā§āύ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
NICE NG236 āĻ āύā§āϏāĻžāϰ⧠Generalised Spasticity-āϤ⧠Oral Baclofen āĻŦāĻŋāĻŦā§āĻā§āϝ; Focal Spasticity-āϤ⧠āϞāĻā§āώā§āϝāĻāĻŋāϤā§āϤāĻŋāĻ Rehabilitation āĻ āĻ āύā§āϝāĻžāύā§āϝ āĻāĻŋāĻāĻŋā§āϏāĻž āĻŦā§āĻļāĻŋ āĻĒā§āϰāĻžāϏāĻā§āĻāĻŋāĻ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
ā§§ā§Ģ. Referral
Primary Referral: Neurology / Neuromedicine
āĻāĻ āϰā§āĻā§āϰ āĻāύā§āϝ āϏāĻŦāĻā§ā§ā§ āĻāĻĒāϝā§āĻā§āϤ āĻĒā§āϰāĻžāĻĨāĻŽāĻŋāĻ Referral āĻšāϞ⧠Neurology / NeuromedicineāĨ¤
āĻĒā§āϰā§ā§āĻāύ āĻ āύā§āϝāĻžā§ā§ Physical Medicine & Rehabilitation-āĻāĻ Refer āĻāϰāĻž āĻāĻāĻŋāϤāĨ¤
Cardiology Referral āĻĒā§āϰā§ā§āĻāύ āĻšāϤ⧠āĻĒāĻžāϰ⧠āϝāĻĻāĻŋ Atrial Fibrillation, Structural Heart Disease, Heart Failure āĻ āĻĨāĻŦāĻž Cardioembolic Stroke-āĻāϰ āϏāύā§āĻĻā§āĻš āĻĨāĻžāĻā§āĨ¤
Prescription Referral Note
Referred to Neurology / Neuromedicine Specialist for evaluation of previous ischemic stroke, assessment of possible residual neurological deficits and post-stroke pain/spasticity, medication review, and optimisation of secondary stroke prevention.
ā§§ā§Ŧ. Overview / Summary
â Final Working Diagnosis
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āύāĻĨāĻŋāĻā§āĻā§āϤ āϤāĻĨā§āϝ āĻ āύā§āϝāĻžā§ā§ āϏāĻŦāĻā§ā§ā§ āĻāĻĒāϝā§āĻā§āϤ Diagnosis:
1. H/O Ischemic Stroke
2. H/O Hypertension (HTN)
āĻŦāĻžāĻāϞāĻžā§:
āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āĻāϏā§āĻā§āĻŽāĻŋāĻ āϏā§āĻā§āϰā§āĻ āĻ āĻāĻā§āĻ āϰāĻā§āϤāĻāĻžāĻĒā§āϰ āĻāϤāĻŋāĻšāĻžāϏāĨ¤
āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϏāĻšāĻžāĻŦāϏā§āĻĨāĻžāύāĻāĻžāϰ⧠āϏāĻŽāϏā§āϝāĻž:
Possible Post-Stroke Neuropathic Pain and/or Spasticity â Clinical Confirmation Required.
Algaba 50 mg āϏāĻ āĻŋāĻāĻāĻžāĻŦā§ āĻļāύāĻžāĻā§āϤ āĻšāĻā§āĻžāϰ āĻĢāϞ⧠āϰā§āĻā§āϰ āϏāĻŽā§āĻāĻžāĻŦā§āϝ Neuropathic Pain āĻŽā§āϞā§āϝāĻžā§āύā§āϰ āĻā§āϰā§āϤā§āĻŦ āĻŦā§ā§ā§āĻā§āĨ¤ āĻāĻŋāύā§āϤ⧠āĻļā§āϧ⧠Pregabalin āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻžāϰāĻŖā§ Neuropathic Pain āĻŦāĻž Post-Stroke Epilepsy āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āϝāĻžā§ āύāĻžāĨ¤
Prescription-āĻ Dx āĻā§ āϞāĻŋāĻāĻŦā§āύ?
Dx: H/O Ischemic Stroke with HTN.
āĻŦāϰā§āϤāĻŽāĻžāύ Neurological Examination-āĻ Residual Deficit, Neuropathic Pain āĻ āĻĨāĻŦāĻž Spasticity āύāĻŋāĻļā§āĻāĻŋāϤ āĻšāϞ⧠āϏāĻāĻļā§āϞāĻŋāώā§āĻ Diagnosis āϝā§āĻā§āϤ āĻāϰāĻŦā§āύāĨ¤
ā§§ā§. Actionable Clinical Plan
Priority 1 â Drug Safety: Reservix 100 mg āϏāϤā§āϝāĻŋāĻ Aceclofenac āĻāĻŋ āύāĻž āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰā§āύāĨ¤ Stroke History-āĻāϰ āϏāĻā§āĻā§ āĻāĻāĻŋ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ Safety ConcernāĨ¤
Priority 2 â Neurological Assessment: āĻŦāϰā§āϤāĻŽāĻžāύ⧠āĻĻā§āϰā§āĻŦāϞāϤāĻž, Sensory Change, Neuropathic Pain āĻ Spasticity āĻāĻā§ āĻāĻŋ āύāĻž āĻĒāϰā§āĻā§āώāĻž āĻāϰā§āύāĨ¤
Priority 3 â Stroke Review: āĻĒā§āϰā§āύ⧠CT/MRI, Stroke Etiology āĻāĻŦāĻ āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻāĻžāĻāĻāĻĒāϤā§āϰ āϏāĻāĻā§āϰāĻš āĻāϰā§āύāĨ¤
Priority 4 â Risk-factor Assessment: BP, LDL-C, HbA1c, ECG āĻāĻŦāĻ āĻĒā§āϰā§ā§āĻāύ āĻ āύā§āϝāĻžā§ā§ Renal Function āĻĒāϰā§āĻā§āώāĻž āĻāϰā§āύāĨ¤
Priority 5 â Medication Review: Algaba āĻ Beklo-āĻāϰ āĻĒā§āϰā§ā§āĻāύā§ā§āϤāĻž, Response, Renal Dose āĻāĻŦāĻ Sedation/Fall Risk āĻŽā§āϞā§āϝāĻžā§āύ āĻāϰā§āύāĨ¤
āύāϤā§āύ āĻāϰ⧠āĻāĻ āĻĒāĻžāĻļ āĻĻā§āϰā§āĻŦāϞ āĻšāĻā§āĻž, āĻŽā§āĻ āĻŦā§āĻāĻā§ āϝāĻžāĻā§āĻž, āĻāĻĨāĻž āĻā§āĻŋā§ā§ āϝāĻžāĻā§āĻž āĻŦāĻž āĻšāĻ āĻžā§ āĻĻā§āώā§āĻāĻŋāĻļāĻā§āϤāĻŋāϰ āϏāĻŽāϏā§āϝāĻž āĻšāϞ⧠āĻāϰā§āϰāĻŋ Stroke Service-āĻ āĻĒāĻžāĻ āĻžāϤ⧠āĻšāĻŦā§āĨ¤
ā§§ā§Ž. Reference List
Textbooks
- Harrisonâs Principles of Internal Medicine. 22nd Edition. McGraw Hill, 2025. Chapter 437: Introduction to Cerebrovascular DiseasesāĨ¤
- Katzungâs Basic & Clinical Pharmacology. 16th Edition. McGraw Hill, 2024. Relevant sections on Antiplatelets, Statins, Anticonvulsants and Muscle RelaxantsāĨ¤
- Goodman & Gilmanâs The Pharmacological Basis of Therapeutics. 14th Edition. McGraw Hill, 2023. Relevant chapters on Cardiovascular Pharmacology and CNS DrugsāĨ¤
Clinical Guidelines
- AHA/ASA (2021). Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke. 2021;52:e364âe467. DOI: 10.1161/STR.0000000000000375.
- NICE NG236 (2023). Stroke Rehabilitation in Adults.
- NICE CG173 (updated 2020). Neuropathic Pain in Adults: Pharmacological Management in Non-specialist Settings.
- UK MHRA (2015). Aceclofenac: Updated Cardiovascular Advice.
Drug Reference
- MedEx Bangladesh: Ecosprin, ATV, Algaba, Reservix, Losectil āĻāĻŦāĻ Beklo-āĻāϰ Brand-specific Drug MonographsāĨ¤
Final Clinical Conclusion
āĻāĻĒāύāĻžāϰ āϏāĻāĻļā§āϧāĻŋāϤ Algaba 50 mg = Pregabalin 50 mg MedEx-āĻ āύāĻŋāĻļā§āĻāĻŋāϤ āĻšā§ā§āĻā§āĨ¤
āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āύāĻĨāĻŋāĻā§āĻā§āϤ āĻŽā§āϞ Diagnosis āĻāĻŦāĻ āĻāĻŽāĻžāϰ Working Diagnosis āĻāĻāĻ: H/O Ischemic Stroke with HTNāĨ¤
āϤāĻŦā§ āĻāĻŦāĻžāϰ āĻĻā§āĻāĻŋ āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āĻŦāĻŋāώ⧠āĻŽā§āϞā§āϝāĻžā§āύ⧠āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ:
āĻĒā§āϰāĻĨāĻŽāϤ, Algaba āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻžāϰāĻŖā§ Neuropathic Pain-āĻāϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āϰā§ā§āĻā§āĨ¤
āĻĻā§āĻŦāĻŋāϤā§ā§āϤ, Beklo āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻžāϰāĻŖā§ Post-Stroke Spasticity-āĻāϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āϰā§ā§āĻā§āĨ¤
āĻĻā§āĻāĻŋāĻ Clinical Examination āĻĻāĻŋā§ā§ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
āϏāĻŦāĻā§ā§ā§ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ Medication Safety Finding: Reservix āϝāĻĻāĻŋ Aceclofenac āĻšā§, āϤāĻžāĻšāϞ⧠āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠Ischemic Stroke-āĻāϰ āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠āĻĒā§āϰā§āϏāĻā§āϰāĻžāĻāĻŦāĻŋāĻ āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āϏāĻā§āĻā§ āĻāϰ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻĻā§āϰā§āϤ āĻĒāϰā§āϝāĻžāϞā§āĻāύāĻž āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Md.Rafiqul Islam Lipu.